Basic Information
| LncRNA/CircRNA Name | SNHG16 |
| Synonyms | SNHG16, Nbla10727, Nbla12061, ncRAN |
| Region | GRCh38_17:76557766-76565348 |
| Ensemble | ENSG00000163597 |
| Refseq | NR_038108 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, RNA immunoprecipitation |
| Sample | bladder cancer tissues, bladder cancer cells (T-24, BIU87, and 5637) |
| Expression Pattern | up-regulated |
| Function Description | the level of SNHG16 was evidently enhanced both in tissues and cell lines of bladder cancer. Patients with highly expressed SNHG16 suffered from poor overall survival. Multivariable Cox proportional hazards regression analysis implied that highly expressed SNHG16 could be used as an independent prognostic marker. It could be known from functional assays that silenced SNHG16 impaired cell proliferation, owing to the effects of SNHG16 on cell cycle and apoptosis. Finally, mechanism experiments revealed that SNHG16 could epigenetically silence the expression of p21. |
| Pubmed ID | 29234154 |
| Year | 2017 |
| Title | LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. |
External Links
| Links for SNHG16 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |